Treasury Management – Game Towne http://gametowne.com/ Fri, 17 Sep 2021 22:07:06 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://gametowne.com/wp-content/uploads/2021/06/icon-6-150x150.png Treasury Management – Game Towne http://gametowne.com/ 32 32 Illinois People Encouraged To Take Action To Fight Hunger During Tackle Hunger Month | Best Stories https://gametowne.com/illinois-people-encouraged-to-take-action-to-fight-hunger-during-tackle-hunger-month-best-stories/ https://gametowne.com/illinois-people-encouraged-to-take-action-to-fight-hunger-during-tackle-hunger-month-best-stories/#respond Fri, 17 Sep 2021 19:49:00 +0000 https://gametowne.com/illinois-people-encouraged-to-take-action-to-fight-hunger-during-tackle-hunger-month-best-stories/ SPRINGFIELD, Ill. (WAND) – Residents of Illinois are encouraged to take action to tackle hunger this September. The Day of Action Against Hunger, which is Friday, September 17, is part of Fight against hunger month. The initiative is a campaign put together by Feeding America, the nation’s largest anti-hunger organization. Feeding America has a nationwide […]]]>

SPRINGFIELD, Ill. (WAND) – Residents of Illinois are encouraged to take action to tackle hunger this September.

The Day of Action Against Hunger, which is Friday, September 17, is part of Fight against hunger month. The initiative is a campaign put together by Feeding America, the nation’s largest anti-hunger organization. Feeding America has a nationwide network of 200 food banks.

Springfield’s Central Illinois Foodbank on Friday encourages people to take the following actions:

  • Donate or volunteer at the local food bank or pantry
  • Wear orange and start a conversation about hunger on September 17th
  • Share posts on social media using the hashtag #HungerActionCentralIL until the end of the month

“Hunger is an issue that concerns us 365 days a year, and Action Against Hunger Month is an opportunity for everyone to think about how best to support our neighbors,” said Pam Molitoris, Executive Director of the Central Illinois Foodbank. “As many of our neighbors struggle to get back on their feet after a difficult year and a half, it’s important to remember that food shouldn’t be an impossible choice. “

For this effort, the Foodbank has partnered with Hickory Point Bank to raise money to fight hunger in central and southern Illinois. The bank will donate $ 10 for each post using #HungerActionCentralIL until the end of September.

“Hickory Point Bank is a local bank with a history of local connections to Springfield,” said Janice Schramm, vice president of cash management services for Hickory Point Bank. “Supporting Central Illinois Foodbank Hunger Action Month is creating a wave of change in the community, and we are proud to support this positive effort. “

There is 1 in 8 people (around 100,000 people) facing hunger or food insecurity in the 21 counties that are part of the Food Bank’s service area.


Source link

]]>
https://gametowne.com/illinois-people-encouraged-to-take-action-to-fight-hunger-during-tackle-hunger-month-best-stories/feed/ 0
First Merchants Co. (NASDAQ: FRME) Receives Average Analyst ‘Buy’ Recommendation https://gametowne.com/first-merchants-co-nasdaq-frme-receives-average-analyst-buy-recommendation/ https://gametowne.com/first-merchants-co-nasdaq-frme-receives-average-analyst-buy-recommendation/#respond Fri, 17 Sep 2021 09:24:05 +0000 https://gametowne.com/first-merchants-co-nasdaq-frme-receives-average-analyst-buy-recommendation/ First Merchants Co. (NASDAQ: FRME) has been given a consensus rating of “Buy” from the six brokerages that currently cover the stock, reports Marketbeat Ratings. One research analyst rated the stock with a keep recommendation and four gave the company a buy recommendation. The 1-year average price target among brokers who updated their stock coverage […]]]>

First Merchants Co. (NASDAQ: FRME) has been given a consensus rating of “Buy” from the six brokerages that currently cover the stock, reports Marketbeat Ratings. One research analyst rated the stock with a keep recommendation and four gave the company a buy recommendation. The 1-year average price target among brokers who updated their stock coverage in the past year is $ 39.50.

A number of equity research analysts have recently commented on FRME stocks. Janney Montgomery Scott downgraded First Merchants from a “neutral” rating to a “buy” rating and set a price target of $ 48.00 on the stock in a research report on Thursday, July 29. Zacks investment research downgraded First Merchants from a “buy” rating to a “keep” rating in a research report on Friday, August 13. Finally, Raymond James lowered his price target on First Merchants from $ 55.00 to $ 47.00 and set an “outperform” rating on the stock in a research report published on Wednesday, July 28.

Institutional investors and hedge funds have recently changed their positions in the company. Cullen Frost Bankers Inc. purchased a new position in First Merchants in the second quarter valued at $ 26,000. Berman Capital Advisors LLC purchased a new position in First Merchants shares in the 1st quarter valued at $ 28,000. William Blair Investment Management LLC purchased a new position in First Merchants shares in the second quarter valued at $ 70,000. Federated Hermes Inc. strengthened its position in First Merchants shares by 18.7% in the 2nd quarter. Federated Hermes Inc. now owns 2,569 shares of the bank valued at $ 107,000 after purchasing an additional 404 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. bought in the 1st quarter a new position in First Merchants shares for an amount of $ 151,000. Hedge funds and other institutional investors hold 73.89% of the company’s shares.

(A d)

If you’ve watched The Big Short movie, you’ve heard of Michael Burry.

He was one of the few who predicted the 2008 crash. Now he’s warning the “mother of all crashes” is coming.

If you have money in the markets I invite you to click here and get the exact day of the next stock market crash.

Actions of FRME opened for $ 39.03 on Friday. First Merchants has a one-year minimum of $ 21.50 and a one-year maximum of $ 50.65. The company has a current ratio of 0.78, a quick ratio of 0.78 and a debt ratio of 0.24. The stock has a 50-day simple moving average of $ 40.72 and a 200-day simple moving average of $ 43.95. The stock has a market cap of $ 2.11 billion, a PE ratio of 11.35 and a beta of 1.29.

First Merchants (NASDAQ: FRME) last released its results on Sunday, July 25. The bank reported earnings per share (EPS) of $ 1.03 for the quarter, beating the Zacks’ consensus estimate by $ 0.92 by $ 0.11. First Merchants recorded a return on equity of 10.09% and a net margin of 33.81%. The company posted revenue of $ 135.15 million in the quarter, compared to analysts’ expectations of $ 131.17 million. On average, seller-side analysts predict that First Merchants will post 3.78 EPS for the current fiscal year.

The company also recently unveiled a quarterly dividend, which will be paid on Friday, September 17. Shareholders of record on Friday, September 3 will receive a dividend of $ 0.29. The ex-dividend date of this dividend is Thursday, September 2. This represents a dividend of $ 1.16 on an annualized basis and a return of 2.97%. First Merchants’ payout ratio is 42.34%.

Company Profile First Merchants

First Merchants Corp. (Indiana) is a holding company that provides financial services. It also offers personal banking, business banking, mortgages, cash management and wealth management services. The company was founded in September 1982 and is headquartered in Muncie, IN.

Further reading: Moving Average (MA)

This instant news alert was powered by storytelling technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in First Merchants now?

Before you consider First Merchants, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold … and First Merchants was not on the list.

While First Merchants currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here


Source link

]]>
https://gametowne.com/first-merchants-co-nasdaq-frme-receives-average-analyst-buy-recommendation/feed/ 0
Business First Bancshares: joins the REACh project to help minority banks https://gametowne.com/business-first-bancshares-joins-the-reach-project-to-help-minority-banks/ https://gametowne.com/business-first-bancshares-joins-the-reach-project-to-help-minority-banks/#respond Thu, 16 Sep 2021 21:52:10 +0000 https://gametowne.com/business-first-bancshares-joins-the-reach-project-to-help-minority-banks/ Baton Rouge, Louisiana – b1BANK is pleased to announce its partnership with Project REACh, an interagency initiative led by the Office of the Comptroller of the Currency (OCC). REACh, or Round Table for Economic Access and Change, brings together community leaders to reduce specific barriers to full, equal and fair participation in the country’s economy.This […]]]>

Baton Rouge, Louisiana – b1BANK is pleased to announce its partnership with Project REACh, an interagency initiative led by the Office of the Comptroller of the Currency (OCC). REACh, or Round Table for Economic Access and Change, brings together community leaders to reduce specific barriers to full, equal and fair participation in the country’s economy.This collaboration is part of the bank’s ongoing Community Development and Economic Development and Sustainability (CSI) Initiative, which seeks collaborative opportunities that can meet the needs of underserved people in the bank’s communities.

“B1BANK responds to the need for greater financial inclusion, which is why we are striving to develop closer relationships with community banks that serve low and moderate income census tracts,” said Jesse Jackson, vice-president. executive chairman and chairman of the b1BANK financial institutions group. . “When it comes to financial inclusion, b1BANK understands the material business benefits and social impact of the commitment to support Project Reach. “

B1BANK’s intention is to help minority deposit-taking institutions (MDIs) remain a dynamic part of the economic landscape and better promote fair, equal and full access to financial products and services in their communities. As a REACh project partner, b1BANK will work with individual MDIs to identify investment opportunities that will benefit the MDI. The bank will also help MDI to implement new and relevant products and services, innovative technology initiatives, seek opportunities to expand the reach of MDI, and connect MDI to community leaders and organizations for business and growth opportunities. .

About Business First Bancshares, Inc.

Business First Bancshares, Inc., through its banking subsidiary b1BANK, formerly known as Business First Bank, operates 42 banking centers and two loan production offices in the Louisiana and Dallas area markets. , in Texas. b1BANK provides commercial and personal banking, cash management and wealth solutions to small and medium businesses as well as their owners and employees. Visit www.b1BANK.com for more information. Business First common stock trades on the NASDAQ Global Select Market under the symbol “BFST”.

Forward-looking statements

The statements contained in this press release may not be based on historical fact and may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may be identified by reference to future periods . or by the use of forward-looking terminology, such as “anticipate”, “estimate”, “expect”, “foresee”, “may”, “could”, “may”, “wish”, “could” “Or” could “or” could “, ‘the tenses of verbs in the future or conditional, and variations or negatives of these terms. Any forward-looking statement speaks only as of the date of this press release, and Business First assumes no obligation, and specifically disclaims any obligation, to revise or update such forward-looking statements, whether as a result of new information, future developments or others.

###

Read the full version


Source link

]]>
https://gametowne.com/business-first-bancshares-joins-the-reach-project-to-help-minority-banks/feed/ 0
AbbVie dodges hedge fund lawsuit over failed $ 55 billion Shire lawsuit https://gametowne.com/abbvie-dodges-hedge-fund-lawsuit-over-failed-55-billion-shire-lawsuit/ https://gametowne.com/abbvie-dodges-hedge-fund-lawsuit-over-failed-55-billion-shire-lawsuit/#respond Tue, 14 Sep 2021 20:00:00 +0000 https://gametowne.com/abbvie-dodges-hedge-fund-lawsuit-over-failed-55-billion-shire-lawsuit/ AbbVie has not been short of criticism and questioning over its decision to drop its $ 55 billion Shire buyout in 2014. But after years of legal back-and-forth, the company has escaped a High-profile hedge fund case which alleged the company has misled them about its true intentions. When AbbVie unveiled its proposed deal with […]]]>

AbbVie has not been short of criticism and questioning over its decision to drop its $ 55 billion Shire buyout in 2014. But after years of legal back-and-forth, the company has escaped a High-profile hedge fund case which alleged the company has misled them about its true intentions.

When AbbVie unveiled its proposed deal with Shire in July 2014, the company cited “strong strategic rationale” for the move, and not just the tax benefits of acquiring an Irish drugmaker. But shortly after the US Treasury Department put new rules in place in September 2014 to crack down on controversial so-called tax reversals, the company backed out of the merger.

This sequence of events resulted in heavy losses in hedge funds, which then sued AbbVie for fraud. In their lawsuits, the hedge funds said they bought Shire shares in hopes the deal would go through, but suffered losses when AbbVie pulled out of the deal in October 2014. They said AbbVie’s public statements did not match his private intentions to sue Shire.

In a ruling on Monday, Cook County Circuit Judge Margaret A. Brennan ruled in AbbVie’s favor, granting summary judgment and dismissing the hedge fund claims. The plaintiffs were “kind of rolling the dice, hoping to make some money” by buying Shire stock after the buyout was announced, the judge said. They “had to do their own analysis” and “should be aware that there was a possibility that this would not materialize,” she added.

Representing AbbVie, Gabor Balassa of law firm Kirkland Ellis said the company’s statements on merger talks, before and after the July 14, 2014 announcement, contained caveats and opinions on the proposed deal. , not statements of fact.

RELATED: Hedge Fund Sues AbbVie for Scuttling $ 55 Billion Shire Buyout

Hedge funds saw it differently. Representing the plaintiffs, Robert B. Tannenbaum of Bartlit Beck said AbbVie had “on several occasions” told its clients that the deal was “not driven by tax benefits” but was “strategically and financially. convincing far beyond the tax advantages “. This did not match the company’s hidden beliefs, Tannenbaum told the court, as evidenced by the company’s decision to withdraw from the deal after the US Treasury Department rolled out its anti-reverse rules.

Even after the US Treasury Department released these rules, AbbVie CEO Richard Gonzalez noted in a note to Shire employees that he was “more confident than ever in the potential of our combined organizations,” said Tannenbaum.

Behind the scenes, AbbVie executives sought the deal primarily for tax purposes, Tannenbaum said. At the time, tax reversals were “extremely controversial and almost universally unpopular.” In this environment, AbbVie developed a “messaging strategy”, he said, to talk about the most favorable aspects of the deal.

AbbVie pursued this false messaging strategy to minimize the government’s scrutiny of the deal, avoid damaging long-term reputation as tax evasion, and avoid losing the essential support of Shire shareholders for the deal, ”Tannenbaum said.

SPECIAL FEATURE: The main promises broken, broken or abandoned by Biopharma | AbbVie, Rick Gonzalez

In 2016, hedge fund Elliott Management sued AbbVie for the failed merger, and other funds followed their own lawsuits in subsequent years. The discovery in litigation went on for years, with attorneys taking nearly 100 depositions.

In another case, AbbVie settled with Shire shareholders in 2019 for an undisclosed amount.

After AbbVie and Shire parted ways during their talks, Takeda ended up buying the Irish drugmaker in 2018 for $ 62 billion. AbbVie, for its part, marked another mega-merger with its massive buyout of Allergan. AbbVie and Allergan merged last May in a $ 63 billion deal.


Source link

]]>
https://gametowne.com/abbvie-dodges-hedge-fund-lawsuit-over-failed-55-billion-shire-lawsuit/feed/ 0
Stripe discusses public listing for 2022 with bankers https://gametowne.com/stripe-discusses-public-listing-for-2022-with-bankers/ https://gametowne.com/stripe-discusses-public-listing-for-2022-with-bankers/#respond Fri, 10 Sep 2021 20:44:44 +0000 https://gametowne.com/stripe-discusses-public-listing-for-2022-with-bankers/ (Bloomberg) – Stripe Inc., the latest digital payments company valued at nearly $ 100 billion, is in preliminary talks with investment banks to go public as early as next year, according to people with knowledge of the matter. The 11-year-old company plans to debut through a direct listing or an initial public offering, the people […]]]>

(Bloomberg) – Stripe Inc., the latest digital payments company valued at nearly $ 100 billion, is in preliminary talks with investment banks to go public as early as next year, according to people with knowledge of the matter.

The 11-year-old company plans to debut through a direct listing or an initial public offering, the people said, asking not to be identified because the information was private. His plans, including the timeline, could still change, the people said.

A representative for Stripe, headquartered in Dublin and San Francisco, declined to comment.

Stripe, founded by brothers John and Patrick Collison, is one of the most anticipated listings in years and one of the largest privately held companies to ever go public. Already, the Collisons each have a net worth of $ 11.4 billion, according to the Bloomberg Billionaires Index.

Stripe raised $ 600 million in March for a valuation of $ 95 billion. This makes it the most valuable American startup and one of the largest in the world alongside TikTok’s parent company ByteDance Ltd, according to data provider CB Insights.

In the months following this assessment, private transactions were considerably higher. Existing investors were able to sell shares at a price that sets the company at $ 152 billion, according to data provider PitchBook.

Direct registration

If it pursues a direct listing, it would be the latest in a growing list of companies to take the less conventional route developed by Spotify Technology SA in 2018. In a direct listing, investors in a company can usually start to sell their shares on the public market. without new shares being issued to raise capital for the company.

Reuters reported in July that the company had hired Cleary Gottlieb Steen & Hamilton LLP as legal counsel for its early stage listing preparations.

Stripe competes with Square Inc. and Paypal Holdings Inc. Its products are used by companies such as Amazon.com Inc., Salesforce.com Inc. and Lyft Inc.

Stripe investors include Allianz SE, Axa SA, Baillie Gifford, Fidelity Management & Research Co., Sequoia Capital and the National Treasury Management Agency of Ireland.

(Updates with secondary market valuation from sixth paragraph)

More stories like this are available at bloomberg.com

Subscribe now to stay ahead of the curve with the most trusted source of business information.

© 2021 Bloomberg LP


Source link

]]>
https://gametowne.com/stripe-discusses-public-listing-for-2022-with-bankers/feed/ 0
Invesco Capital LLC – PowerShares UltraShort Lehman 7-10 + Year Treasury ProShares (PST) drops 0.56% in Light Trading on September 9 https://gametowne.com/invesco-capital-llc-powershares-ultrashort-lehman-7-10-year-treasury-proshares-pst-drops-0-56-in-light-trading-on-september-9/ https://gametowne.com/invesco-capital-llc-powershares-ultrashort-lehman-7-10-year-treasury-proshares-pst-drops-0-56-in-light-trading-on-september-9/#respond Fri, 10 Sep 2021 01:40:00 +0000 https://gametowne.com/invesco-capital-llc-powershares-ultrashort-lehman-7-10-year-treasury-proshares-pst-drops-0-56-in-light-trading-on-september-9/ Last prize $ Last trade Switch $ Percentage of change % Open $ Previous Close $ High $ moo $ 52 weeks high $ 52 weeks low $ Market capitalization P / E ratio Volume To exchange PST – Market data and news Invesco Capital Management LLC – PowerShares UltraShort Lehman 7-10 + Year Treasury […]]]>

Invesco Capital Management LLC – PowerShares UltraShort Lehman 7-10 + Year Treasury ProShares (NYSE: PST) fell to close at $ 15.75 on Thursday after losing $ 0.089 (0.56%) on a volume of 39,107 shares. The stock ranged from a high of $ 15.84 to a low of $ 15.73, while the market cap of Invesco Capital LLC – PowerShares UltraShort Lehman 7-10 + Year Treasury ProShares now stands at 58,278. $ 700.

Visit Invesco Capital Management LLC – PowerShares UltraShort Lehman 7-10 + Year Treasury ProShares Profile for more information.

About the New York Stock Exchange

The New York Stock Exchange is the world’s largest stock exchange in terms of market value with over $ 26 trillion. It’s also the leader in initial public offerings, with $ 82 billion raised in 2020, including six of the seven biggest tech deals. 63% of PSPC proceeds in 2020 were raised on the NYSE, including the six biggest deals.

To get more information on Invesco Capital Management LLC – PowerShares UltraShort Lehman 7-10 + Year Treasury ProShares and keep up with the latest company updates, you can visit the Company Profile page here: Invesco Capital Management LLC – PowerShares UltraShort Lehman 7-10 + Year Profile of Treasury ProShares. For more information on the financial markets, be sure to visit Equities News. Also, don’t forget to sign up for the Daily Fix to get the best stories delivered to your inbox 5 days a week.

Sources: The chart is provided by TradingView based on 15 minute lag prices. All other data is provided by IEX Cloud as of 8:05 p.m. ET on the day of publication.

DISCLOSURE:
The views and opinions expressed in this article are those of the authors and do not represent the views of equities.com. Readers should not take the author’s statements as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please visit: http://www.equities.com/disclaimer


Unemployment claims drop to 310,000 – lowest in nearly 18 months


200 Westerners on a Qatar Airways flight from Kabul

Pennsylvania Republican lawmakers launch election integrity inquiry

President Biden and Congressional Democrats push for civilian climate body

Biden administration to unveil plan to cut prescription drug prices under Medicare

Hurricane Ida toll in Louisiana rises to 26

Minorities and children suffered increased hunger in 2020 despite federal pandemic aid

Australia’s High Court Holds Media Companies Responsible for Third-Party Comments on Their Facebook Pages



Source link

]]>
https://gametowne.com/invesco-capital-llc-powershares-ultrashort-lehman-7-10-year-treasury-proshares-pst-drops-0-56-in-light-trading-on-september-9/feed/ 0
bluebird bio announces key leadership and board appointments and upcoming investor events https://gametowne.com/bluebird-bio-announces-key-leadership-and-board-appointments-and-upcoming-investor-events/ https://gametowne.com/bluebird-bio-announces-key-leadership-and-board-appointments-and-upcoming-investor-events/#respond Tue, 07 Sep 2021 20:05:00 +0000 https://gametowne.com/bluebird-bio-announces-key-leadership-and-board-appointments-and-upcoming-investor-events/ CAMBRIDGE, Mass .– (COMMERCIAL THREAD) –bluebird bio, Inc. (NASDAQ: BLUE) today announced key leadership and board appointments ahead of the company’s planned separation, slated for mid-October 2021. The company also outlined plans for events for the investors and participation in investor conferences leading to the separation. “As we approach separation, we strive to ensure that […]]]>

CAMBRIDGE, Mass .– (COMMERCIAL THREAD) –bluebird bio, Inc. (NASDAQ: BLUE) today announced key leadership and board appointments ahead of the company’s planned separation, slated for mid-October 2021. The company also outlined plans for events for the investors and participation in investor conferences leading to the separation.

“As we approach separation, we strive to ensure that bluebird organic and 2seventy organic have strong management teams and boards of directors to lead each company through its next phase,” said Nick Leschly, Chief Executive Officer. bluebird. “After an intense period of internal work to prepare for the separation, we now look forward to engaging with key external stakeholders to share each company’s plans as we approach our target October separation.”

update of biological management of blue birds

“I am delighted to welcome Gina Consylman to the management team of bluebird bio. Upon the effectiveness of the planned separation, Gina will become the CFO of bluebird bio, ”said Andrew Obenshain, President, Serious Genetic Diseases. “Her previous experience in a similar spin-off operation and helping lead a successful business organization through times of change has already made her an invaluable partner as we go through an important execution phase at bluebird. ”

Gina Consylman joined bluebird in August 2021 as CFO of the Critical Genetic Diseases business, overseeing finance, tax, accounting, treasury, insurance and investor relations. She has over 25 years of experience in finance, investor relations, strategy and business development. Prior to joining bluebird, she was Senior Vice President and Chief Financial Officer at Ironwood Pharmaceuticals. Prior to Ironwood, Gina was Vice President, Corporate Controller and Senior Accountant at Analogic Corporation, a public health and safety technology solutions company, where she oversaw the company’s global accounting and treasury teams. Prior to working at Analogic, Gina held the position of Senior Manager, Corporate Accounting at Biogen Inc., where she led the accounting teams of the US corporate and commercial business units.

Gina sits on the board of directors of Assembly Biosciences, Inc. and Verastem Oncology. Chartered Accountant, Gina began her career in public accounting at Ernst & Young LLP. She holds a BS in Accounting from Johnson & Wales University and an MS in Taxation from Bentley University.

bluebird bio board update

“As the launch of 2seventy bio approaches, I am delighted to welcome Marcela Maus to the board of directors of bluebird bio. As soon as the planned separation takes effect, Marcela will join the board of directors of 2seventy bio, ”said Nick Leschly. “Marcela’s work as a translational physician-researcher in the field of immunology, particularly with regard to T cell immunotherapies and cell therapies in cancer treatment, makes her ideal for providing valuable information to the 2seventy team. ”

Marcela Maus, MD, Ph.D., is currently Associate Professor at Harvard Medical School, Paula O’Keefe Chair in Oncology and Director of Cellular Immunotherapy at the Mass General Cancer Center, as well as attending physician in transplant surgery. hematopoietic cells and cell therapy division of oncology at the Mass General Cancer Center. She is an associate member of the Broad Institute of Harvard and the Massachusetts Institute of Technology (MIT) and an associate member of the Ragon Institute of Mass General Cancer Center, MIT and Harvard. Dr. Maus’ lab focuses on the biology of human T cell activation, costimulation and memory, as well as the application of human T cell therapies to human diseases, including forward and reverse translation. modified T cell therapies in early phase clinical trials.

Dr Maus completed undergraduate studies at MIT and holds graduate degrees (MD, Ph.D.) from the University of Pennsylvania. Dr Maus was trained in Internal Medicine at the University of Pennsylvania and Hematology and Medical Oncology at Memorial Sloan Kettering Cancer Center, is board certified in all three disciplines, and practices medical oncology. She also sits on several scientific and clinical advisory boards for the biotechnology industry as well as external academic medical centers.

Upcoming investor events

The members of the management teams of bluebird bio and 2seventy bio will participate in the following upcoming investor conferences:

  • Morgan Stanley 19e Annual Health Conference

    • bio bluebird: September 10, 2021 at 10:15 a.m.ET

    • Biography of 2seventy: September 9, 2021 at 12:30 p.m. ET

  • Bank of America Global Healthcare Conference 2021

    • bio bluebird: September 16, 2021 at 9:10 a.m.ET

    • Biography of 2seventy: September 17, 2021 at 10:05 am ET

About bluebird bio, Inc.

bluebird bio is a pioneer in gene therapy for a specific purpose. From our head office in Cambridge, MA, we develop gene and cell therapies for serious genetic diseases and cancer, with the goal that people facing life-threatening conditions with limited treatment options can live their lives to the fullest. . Beyond our laboratories, we work to positively disrupt the health system to create access, transparency and education so that gene therapy can become accessible to all who can benefit from it.

bluebird bio is a human enterprise fueled by human stories. We put our care and expertise at the service of a wide range of disorders: cerebral adrenoleukodystrophy, sickle cell anemia, -thalassemia and multiple myeloma, using gene and cell therapy technologies, including gene addition and gene editing. (activated by megaTAL).

bluebird bio has additional nests in Seattle, Washington; Durham, North Carolina; and Zug, Switzerland. For more information visit bluebirdbio.com.

Follow bluebird’s bio on social media: @bluebirdbio, LinkedIn, Instagram and Youtube.

bluebird bio, 2seventy and 2seventy bio are registered trademarks of bluebird bio, Inc.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the financial condition of the company, results of operations, as well as statements concerning the plans and expectations of the company for operations, including timing, leadership, structure, including the allocation of assets between bluebird bio and 2seventy bio, and the impact of a separation; as well as the company’s intention to provide further updates on the separation and related fundraising strategies for bluebird bio and 2seventy. All forward-looking statements are based on management’s current expectations regarding future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those stated or implied. by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that we may not complete the separation on the terms or schedule currently contemplated, if any, achieve the expected benefits of a separation, and a separation could adversely affect to our company, the results of operations and financial position; the risk that the transaction is not exempt from tax; we may not be able to make, in a timely or cost effective manner, the changes necessary to operate as independent businesses; 2 Seventy bio’s lack of independent operating history and the risk that its accounting and other management systems may not be prepared to meet financial reporting and other operating requirements. as an independent public enterprise; dedicated financial and / or strategic sources of funding may not be available on favorable terms; a separation or an announcement thereof may have a negative impact on our ability to attract or retain key personnel; a separation may have a negative impact on the effectiveness of development and marketing efforts on the part of us and that of our partners; our business may be disrupted as a result of the announcement or expectation of separation; and the risk that we may not be able to realize the expected benefits of resizing and restructuring our workforce. For a discussion of other risks and uncertainties, and other important factors, each of which could cause our actual results to differ from those contained in forward-looking statements, see the section entitled “Risk Factors” in our Form 10 -Q most recent. , as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of publication, and bluebird bio makes no commitment to update such information, except as required by law.



Source link

]]>
https://gametowne.com/bluebird-bio-announces-key-leadership-and-board-appointments-and-upcoming-investor-events/feed/ 0
Insider Buyers: Texas Capital Bancshares, Inc. (NASDAQ: TCBI) Insider buys 4,173 shares https://gametowne.com/insider-buyers-texas-capital-bancshares-inc-nasdaq-tcbi-insider-buys-4173-shares/ https://gametowne.com/insider-buyers-texas-capital-bancshares-inc-nasdaq-tcbi-insider-buys-4173-shares/#respond Fri, 03 Sep 2021 14:18:55 +0000 https://gametowne.com/insider-buyers-texas-capital-bancshares-inc-nasdaq-tcbi-insider-buys-4173-shares/ Texas Capital Bancshares, Inc. (NASDAQ: TCBI) insider Timothy J. Storms purchased 4,173 shares of Texas Capital Bancshares in a trade dated Thursday, September 2. The shares were purchased at an average price of $ 59.83 per share, for a total value of $ 249,670.59. After the purchase was completed, the insider now owns 7,717 shares […]]]>

Texas Capital Bancshares, Inc. (NASDAQ: TCBI) insider Timothy J. Storms purchased 4,173 shares of Texas Capital Bancshares in a trade dated Thursday, September 2. The shares were purchased at an average price of $ 59.83 per share, for a total value of $ 249,670.59. After the purchase was completed, the insider now owns 7,717 shares of the company, valued at approximately $ 461,708.11. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

TCBI traded at $ 0.32 during Friday trading hours, reaching $ 59.87. 1,759 shares were traded, for an average volume of 695,937. The share has a 50-day simple moving average of $ 64.04 and a 200-day simple moving average of $ 69.26. Texas Capital Bancshares, Inc. has a 12-month low of $ 29.44 and a 12-month high of $ 93.26. The stock has a market cap of $ 3.03 billion, a price-to-earnings ratio of 12.38 and a beta of 1.83. The company has a leverage ratio of 1.04, a current ratio of 1.09, and a quick ratio of 1.09.

Texas Capital Bancshares (NASDAQ: TCBI) last released its results on Tuesday, July 20. The bank reported earnings per share of $ 1.31 for the quarter, beating Thomson Reuters consensus estimate of $ 1.21 by $ 0.10. Texas Capital Bancshares recorded a return on equity of 9.64% and a net margin of 23.37%. The company posted revenue of $ 227.10 million for the quarter, compared to analysts’ estimates of $ 240.67 million. During the same period last year, the company made a profit of $ 0.82 per share. The company’s revenue for the quarter was down 19.3% year-on-year. Sell-side analysts expect Texas Capital Bancshares, Inc. to post EPS of 4.97 for the current year.

(A d)

Learn how to join the biggest investing event in over 400 years for just $ 49 (normally $ 199!)

Several equity analysts recently commented on the company. Hovde Group upgraded Texas Capital Bancshares from an “outperformance” rating to a “market performance” rating in a research note Thursday. Truist downgraded Texas Capital Bancshares from a “custody” rating to a “buy” rating and raised its target price for the company from $ 73.00 to $ 85 in a research note on Tuesday, May 11. Wedbush downgraded Texas Capital Bancshares from an “outperforming” rating to a “neutral” rating in a research note Thursday. Raymond James reduced his target price on Texas Capital Bancshares from $ 78.00 to $ 75 and established an “outperformance” rating for the company in a research note Thursday. They noted that the move was an appraisal call. Finally, Stephens reduced his price target on Texas Capital Bancshares from $ 77.00 to $ 75 and set an “overweight” rating for the company in a research note on Thursday, July 22. An equity research analyst rated the stock with a sell rating, six assigned a conservation rating, and six assigned a buy rating to the company. According to MarketBeat, the company currently has an average “Hold” rating and a consensus target price of $ 72.36.

A number of hedge funds and other institutional investors have recently changed their holdings to TCBI. FMR LLC increased its position in Texas Capital Bancshares by 178,572.6% in the first quarter. FMR LLC now owns 150,085 shares of the bank valued at $ 8,194,000 after purchasing an additional 150,001 shares during the period. Strs Ohio increased its position in Texas Capital Bancshares by 69.6% in the first quarter. Strs Ohio now owns 3,900 shares of the bank valued at $ 276,000 after purchasing an additional 1,600 shares during the period. Convergence Investment Partners LLC acquired a new stake in Texas Capital Bancshares in the first quarter for a value of $ 102,000. Virginia Retirement Systems ET AL acquired a new stake in Texas Capital Bancshares in the first quarter valued at $ 213,000. Finally, State of Michigan Retirement System increased its stake in Texas Capital Bancshares by 1.6% in the first quarter. The Michigan state pension system now owns 18,661 shares of the bank valued at $ 1,323,000 after purchasing an additional 300 shares during the period.

Texas Capital Bancshares Company Profile

Texas Capital Bancshares, Inc. is the holding company for Texas Capital Bank NA. It provides commercial banking services to clients in Texas and focuses on mid-market business ventures and successful professionals and entrepreneurs. The firm loan portfolio includes commercial loans, real estate loans, construction loans and letters of credit; business deposit products include commercial chequing accounts, safe deposit boxes, cash concentration accounts and other cash management services, including an online system; trust and wealth management services include investment management, personal trust and estate services, custodial services, retirement accounts and related services.

Further Reading: How Does Equity Income Fit Into An Investment Strategy?

This instant news alert was powered by narrative science technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Texas Capital Bancshares right now?

Before you consider Texas Capital Bancshares, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts are quietly asking their clients to buy now before the broader market takes hold of… and Texas Capital Bancshares was not on the list.

While Texas Capital Bancshares currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here


Source link

]]>
https://gametowne.com/insider-buyers-texas-capital-bancshares-inc-nasdaq-tcbi-insider-buys-4173-shares/feed/ 0
Extension of the deadline! | Cash flow and risk https://gametowne.com/extension-of-the-deadline-cash-flow-and-risk/ https://gametowne.com/extension-of-the-deadline-cash-flow-and-risk/#respond Tue, 31 Aug 2021 21:56:32 +0000 https://gametowne.com/extension-of-the-deadline-cash-flow-and-risk/ If your organization has carried out an innovative project in the area of ​​treasury, finance or risk management, Cash flow and risk I would love to consider it for our 26th Annual Alexander Hamilton Awards. This year’s awards will recognize achievement in seven categories: Cash transformation Liquidity management Financial risk management Working capital and payments […]]]>

If your organization has carried out an innovative project in the area of ​​treasury, finance or risk management, Cash flow and risk I would love to consider it for our 26th Annual Alexander Hamilton Awards. This year’s awards will recognize achievement in seven categories:

  • Cash transformation
  • Liquidity management
  • Financial risk management
  • Working capital and payments
  • Operational risk management and insurance
  • Technological excellence
  • Good practices in small / emerging markets

We may also reward an organization with an overall excellence award, depending on whether our judges feel such an award is deserved based on the various entries received in the seven categories of the competition.

The Alexander Hamilton Awards recognize all types of organizations, from mid-sized national companies to some of the largest companies in the world. Recent award winners range from Microsoft, Walmart and Corning to Charter Hall, Bandwidth, Stanley Black & Decker and Brose Fahrzeugteile. (You can see all of the recent winners here.)

Enter before Friday September 10, 2021, for the chance to be recognized alongside opinion leaders in treasury and finance around the world.


Source link

]]>
https://gametowne.com/extension-of-the-deadline-cash-flow-and-risk/feed/ 0
Analyst Hub announces partnership with 22V Research https://gametowne.com/analyst-hub-announces-partnership-with-22v-research/ https://gametowne.com/analyst-hub-announces-partnership-with-22v-research/#respond Tue, 24 Aug 2021 21:21:34 +0000 https://gametowne.com/analyst-hub-announces-partnership-with-22v-research/ NEW YORK, August 24, 2021 (GLOBE NEWSWIRE) – Today, Analyst Hub is proud to announce a partnership with 22V Research. After nearly 20 years, Dennis DeBusschere left Evercore ISI to launch 22V Research, an independent research boutique focused on investment strategy, quantitative research, Washington politics, technical analysis and economic projections. DeBusschere will partner with Analyst […]]]>

NEW YORK, August 24, 2021 (GLOBE NEWSWIRE) – Today, Analyst Hub is proud to announce a partnership with 22V Research. After nearly 20 years, Dennis DeBusschere left Evercore ISI to launch 22V Research, an independent research boutique focused on investment strategy, quantitative research, Washington politics, technical analysis and economic projections. DeBusschere will partner with Analyst Hub which will provide proprietary publishing and distribution technology tools as well as compliance, sales, back office and branding services that will help scale the new business faster and more efficiently than build everything in-house.

DeBusschere brings together the 22V research team which currently includes Gerard MacDonell, formerly at Point72 Asset Management, Kim Wallace, the former Assistant Under Secretary for Legislative Affairs for the US Department of the Treasury, as well as Brian Herlihy and Colin Crowley, both previously at Evercore ISI. .

“We couldn’t be happier that we decided to partner with Analyst Hub to provide the publishing and distribution technology, compliance and back office support to help us scale 22V faster and more efficiently than if we decided to hire him and develop it all ourselves, ”said Dennis DeBusschere, president of 22V Research. “The people they employ and the technological tools they provide are truly the best in their class. They’ve built a platform that allows the content creator to own their own business and become a profit center – compared to a bank whose research department is consolidated into a commercial and banking firm, it can be difficult to determine which content creators are costs or benefits. centers. “

22V Research will be headquartered in New York. The name of the company was derived in honor of his late father, Dave DeBusschere, the two-time NBA champion of the New York Knicks and a member of the 1983 NBA Hall of Fame class. The “V” stands for victory.

DeBusschere hopes to move away from the typical model of large institutions driven by what he calls “consumption points” where every customer interaction is meticulously accounted for and can make a phone call like a transaction. He says he hopes for a more complete relationship with customers depending on the subscription level they sign up for. You can read more about 22V Research at https://22vresearch.com.

“We are excited to launch 22V Research and add Dennis’ team to the platform,” said Mike Kronenberg, CEO of Analyst Hub. “His expertise, experience and team are incredible, and we are excited to help him focus on providing unparalleled insight to investors while our team takes care of their technology, distribution, compliance. , its back office and many other needs. “

About Analyst Hub: Since 2018, Analyst Hub has facilitated the launch of dozens of independent research vendor companies and supports their ongoing operations by providing technology and infrastructure that includes publishing tools, institutional CRM distribution and subscriber analytics, institutional compliance, an experienced sales team, access to market data, branding services, website design and hosting, social media management and much more.

Institutional customers wishing to subscribe to the 22V Research product offering should contact sales@analythub.com.

22V research coordinates:
22V research
10 East 53rd Street, 6th Fl.
New York, New York 10021
sales@analysthub.com

Contact details of the analyst center:
Analyst Center
135 Madison Avenue, 6e Ground
New York, New York 10016
sales@analysthub.com


Source link

]]>
https://gametowne.com/analyst-hub-announces-partnership-with-22v-research/feed/ 0